Last reviewed · How we verify

Dexamethasone and ondansetron

Yeditepe University Hospital · FDA-approved active Small molecule

This is a fixed-dose combination of a corticosteroid (dexamethasone) that suppresses inflammation and immune responses, and an antiemetic (ondansetron) that blocks serotonin receptors to prevent nausea and vomiting.

This is a fixed-dose combination of a corticosteroid (dexamethasone) that suppresses inflammation and immune responses, and an antiemetic (ondansetron) that blocks serotonin receptors to prevent nausea and vomiting. Used for Chemotherapy-induced nausea and vomiting (CINV) with anti-inflammatory support, Post-operative nausea and vomiting (PONV) with corticosteroid adjunct.

At a glance

Generic nameDexamethasone and ondansetron
SponsorYeditepe University Hospital
Drug classCorticosteroid + 5-HT3 receptor antagonist combination
TargetGlucocorticoid receptor (dexamethasone); 5-HT3 receptor (ondansetron)
ModalitySmall molecule
Therapeutic areaOncology; Gastroenterology; Post-operative care
PhaseFDA-approved

Mechanism of action

Dexamethasone is a glucocorticoid that reduces inflammation by inhibiting phospholipase A2 and suppressing cytokine production. Ondansetron is a selective 5-HT3 receptor antagonist that blocks serotonin signaling in the chemoreceptor trigger zone and gastrointestinal tract. Together, they address both inflammatory/systemic symptoms and chemotherapy-induced or post-operative nausea and vomiting.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: